CPHI [CHINA PHARMA] 8-K: Item 8.01. Other Events. Dated: December 28, 2016
[Item 8.01. Other Events. Dated: December 28, 2016 CHINA PHARMA HOLDINGS, INC. 8-K 1 cphi8k122716.htm]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Responds to Recent Report Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China BEIJING, China, December 23, 2016 -- Sinovac’s Audit Committee has authorized the commencement of an internal investigation into the allegations made in the report. The Aud]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Responds to Recent Report Sinovac Biotech Ltd.
[Sinovac Responds to Recent Report Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China BEIJING, China, December 23, 2016 -- Sinovac’s Audit Committee has authorized the commencement of an internal investigation into the allegations made in the report. The Aud]
CPHI [CHINA PHARMA] 8-K: (Original Filing)
[Item 5.07 Submission of Matters to a Vote of Security Holders. On December 8, 2016, China Pharma Holdings, Inc. (the "Company") held its annual shareholders meeting for the fiscal year ended December 31, 2015 (the "Annual Meeting"). Holders of 27,271,585 shares of the Company's common stock were pre]
CPHI [CHINA PHARMA] 8-K: Item 5.07 Submission of Matters to a Vote
[Item 5.07 Submission of Matters to a Vote of Security Holders. On December 8, 2016, China Pharma Holdings, Inc. (the "Company") held its annual shareholders meeting for the fiscal year ended December 31, 2015 (the "Annual Meeting"). Holders of 27,271,585 shares of the Company's common stock were pre]
CPHI [CHINA PHARMA] 8-K:
[] [Item 4.01. Effective November 28, 2016, Arshak Davtyan, Inc. (the "Former Accountant") resigned as the independent registered public accounting firm of China Pharma Holdings, Inc., a Nevada corporation (the "Company"). The resignation is primarily a result of the business adjustment of the Former]
CPHI [CHINA PHARMA] 8-K: (Original Filing)
[] [Item 4.01. Effective November 28, 2016, Arshak Davtyan, Inc. (the "Former Accountant") resigned as the independent registered public accounting firm of China Pharma Holdings, Inc., a Nevada corporation (the "Company"). The resignation is primarily a result of the business adjustment of the Former]
BSPM [Biostar Pharmaceuticals] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) ☒ September 30, 2016 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Nu]
BSPM [Biostar Pharmaceuticals] 10-Q: FORM 10-Q (Mark One) ☒ September 30, 2016
[FORM 10-Q (Mark One) ☒ September 30, 2016 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Nu]
BSPM [Biostar Pharmaceuticals] NT 10-Q: (Original Filing)
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o o o (Check One): x o o For Period Ended: September 30, 2016 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained h]
